Cyclerion Therapeutics 3/4/2025 Earnings Report

Cyclerion Therapeutics EPS Results

• Actual EPS: $0.22
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cyclerion Therapeutics Revenue Results

• Actual Revenue: $1.81 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cyclerion Therapeutics Announcement Details

• Date: 3/4/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Cyclerion Therapeutics (NASDAQ:CYCN) is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that focuses on the discovery and development of soluble guanylate cyclase (sGC) modulators. Established in 2018 as a spin‐out from Ironwood Pharmaceuticals, Cyclerion applies its expertise in nitric oxide–sGC–cGMP signaling to develop novel therapies for conditions with high unmet medical needs. The company’s research platform centers on small‐molecule stimulators and activators designed to enhance or restore signaling through the sGC pathway.

The company’s lead candidate, praliciguat, is an oral sGC stimulator initially evaluated in Phase II studies for cardiometabolic and fibrotic conditions, demonstrating pharmacodynamic activity in vascular and metabolic biomarkers. In addition to praliciguat, Cyclerion is advancing other proprietary compounds, including activators intended for hemolytic and inflammatory diseases. These programs leverage the company’s in‐house chemistry and translational biology capabilities to optimize therapeutic profiles and improve patient outcomes.

Cyclerion serves both the U.S. and international markets, engaging with research institutions and potential commercial partners to expand the global reach of its pipeline. The company’s development strategy emphasizes rigorous clinical validation combined with an efficient manufacturing approach, ensuring scalability and quality control for future commercialization efforts.

The leadership team at Cyclerion comprises seasoned executives with deep backgrounds in drug development, regulatory affairs, and commercial strategy. Drawing on experience from leading biotechnology and pharmaceutical organizations, management is committed to advancing the company’s sGC portfolio through late‐stage clinical trials and toward potential regulatory approvals.